Your browser is no longer supported. Please, upgrade your browser.
ONCY Oncolytics Biotech Inc. daily Stock Chart
Oncolytics Biotech Inc.
Index- P/E- EPS (ttm)-0.83 Insider Own1.80% Shs Outstand17.57M Perf Week-7.80%
Market Cap35.32M Forward P/E- EPS next Y-0.74 Insider Trans- Shs Float17.34M Perf Month-1.95%
Income-12.70M PEG- EPS next Q-0.18 Inst Own2.50% Short Float0.53% Perf Quarter-16.60%
Sales- P/S- EPS this Y6.60% Inst Trans- Short Ratio1.36 Perf Half Y-55.03%
Book/sh0.41 P/B4.90 EPS next Y- ROA-95.40% Target Price- Perf Year-57.30%
Cash/sh0.69 P/C2.89 EPS next 5Y- ROE-205.30% 52W Range1.64 - 8.20 Perf YTD11.05%
Dividend- P/FCF- EPS past 5Y24.40% ROI- 52W High-75.49% Beta2.27
Dividend %- Quick Ratio5.50 Sales past 5Y- Gross Margin- 52W Low22.70% ATR0.15
Employees23 Current Ratio5.50 Sales Q/Q- Oper. Margin- RSI (14)46.28 Volatility4.84% 6.51%
OptionableNo Debt/Eq0.00 EPS Q/Q1.40% Profit Margin- Rel Volume0.79 Prev Close2.00
ShortableYes LT Debt/Eq0.00 EarningsFeb 11 BMO Payout- Avg Volume67.26K Price2.01
Recom- SMA20-3.05% SMA50-2.57% SMA200-49.49% Volume53,298 Change0.50%
Feb-11-19 07:00AM  Oncolytics Biotech(R) Announces Spanish Regulatory Approval of AWARE-1 Window of Opportunity Study in Breast Cancer ACCESSWIRE
Feb-04-19 07:00AM  Oncolytics Biotech(R) to Present at the 21st Annual BIO CEO & Investor Conference ACCESSWIRE +5.19%
Dec-12-18 07:00AM  Oncolytics Biotech® Announces First Patient Treated in Study Combining Pelareorep, Carfilzomib and the Checkpoint Inhibitor Opdivo® in Multiple Myeloma GlobeNewswire +10.58%
Dec-03-18 07:00AM  Oncolytics Biotech® Announces Increased PD-L1 Expression When Combining Pelareorep with a Proteasome Inhibitor in Poster Presentation at the 60th American Society of Hematology Annual Meeting & Exposition GlobeNewswire
Nov-29-18 07:00AM  Oncolytics Biotech® Announces Appointment of Rita Laeufle, M.D., as Chief Medical Officer GlobeNewswire
Nov-27-18 07:32AM  The Daily Biotech Pulse: Abeona Fires CEO, Loxo Passes FDA Muster, Bristol-Myers Flunks Lung Cancer Trial Benzinga +6.44%
Nov-26-18 08:00AM  Oncolytics Biotech® Announces First Patient Treated in Phase 2 Study Combining Pelareorep and Keytruda® in Advanced Pancreatic Cancer GlobeNewswire
Nov-13-18 07:00AM  Oncolytics Biotech® Announces Attendance of Upcoming Conferences GlobeNewswire -8.71%
Nov-12-18 07:00AM  Oncolytics Biotech® Reports 2018 Third Quarter Financial Results and Provides Corporate Update GlobeNewswire
Nov-09-18 07:00AM  Oncolytics Biotech® Announces Presentation at the Society for Immunotherapy of Cancer 2018 Annual Meeting Showcasing Upregulation of PD-L1 Expression with Reovirus Infection GlobeNewswire
Nov-05-18 07:00AM  Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Corporate Highlights GlobeNewswire
Nov-01-18 07:00AM  Oncolytics Biotech® Announces Abstract for ASH Annual Meeting & Exposition Demonstrating Pelareorep Increases PD-L1 Expression When Combined with a Proteasome Inhibitor GlobeNewswire -5.86%
Oct-24-18 08:25PM  Oncolytics Biotech® Establishes New At-The-Market Facility GlobeNewswire
Oct-22-18 07:00AM  Oncolytics Biotech® Announces Positive Clinical Trial Results for Pelareorep in Patients with KRAS Mutant Metastatic Colorectal Cancer for Presentation at ESMO 2018 GlobeNewswire
Oct-11-18 07:00AM  Oncolytics Biotech® Announces Publication of Positive Clinical Results for Pelareorep in Abstract for ESMO 2018 Congress GlobeNewswire
Oct-02-18 07:00AM  Oncolytics Biotech® Announces a Publication Demonstrating That Intravenously Delivered Oncolytic Viruses Effectively Target Tumors Even in the Presence of Neutralizing Antibodies GlobeNewswire
Sep-28-18 08:36AM  Oncolytics Biotech® Enters into Common Stock Purchase Agreement for up to US$26 Million with Lincoln Park Capital, LLC GlobeNewswire
Sep-26-18 07:00AM  Oncolytics Biotech® to Present at the Ladenburg Thalmann 2018 Healthcare Conference GlobeNewswire
Sep-19-18 04:00PM  Oncolytics Biotech® Provides Corporate and Clinical Update GlobeNewswire
Sep-17-18 07:00AM  Oncolytics Biotech® Announces Investigator Sponsored Multiple Myeloma Study Combining REOLYSIN® and Nivolumab (Opdivo®) with Standard of Care GlobeNewswire -10.11%
Sep-10-18 07:00AM  Oncolytics Biotech® Collaborates with SOLTI to Conduct a Window of Opportunity Study in Breast Cancer with Pelareorep GlobeNewswire -5.64%
Sep-06-18 07:00AM  Oncolytics Biotech® Announces a Master Clinical Supply Agreement of an Anti-PD-L1 Checkpoint Inhibitor for use in the Companys Clinical Program GlobeNewswire +8.09%
Aug-03-18 07:00AM  Oncolytics Biotech® Reports 2018 Second Quarter Results GlobeNewswire -8.54%
Jul-31-18 07:00AM  Oncolytics Biotech® to Present at the Canaccord Genuity 38th Annual Growth Conference GlobeNewswire
Jun-06-18 10:25AM  ONCY: It Has Been a Busy Week or Two Zacks Small Cap Research
Jun-05-18 12:49PM  Oncolytics Biotech® Closes USD $8.9 Million Public Offering of Common Shares GlobeNewswire +11.52%
Jun-04-18 09:00AM  Oncolytics Biotech® Announces Poster Presentation Demonstrating the Ability of REOLYSIN® to Promote and Predict Response to Checkpoint Inhibitors at ASCO 2018 Annual Meeting GlobeNewswire
Jun-01-18 09:13AM  Oncolytics Biotech® Prices USD $8,000,000 Million Public Offering of Common Shares GlobeNewswire
07:40AM  Oncolytics Biotech® Announces Listing on Nasdaq Capital Market GlobeNewswire
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses. It has a research collaboration with Keck School of Medicine of University of Southern California using pelareorep in combination with Keytruda, Velcade, and dexamethasone to treat multiple myeloma; and a clinical collaboration with SOLTI breast cancer research. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada.